# Targeting the PI3K/AKT signaling pathway: an important molecular mechanism of herbal medicine in the treatment of MASLD/MASH

**Authors:** Shan Jiang, Li Zhai, Yingchun Shao, Fusheng Sun, Xuedong Liu

PMC · DOI: 10.3389/fnut.2025.1743899 · Frontiers in Nutrition · 2026-01-12

## TL;DR

This paper reviews how herbal medicines can treat liver disease by targeting the PI3K/AKT signaling pathway, which is involved in the progression of MASLD/MASH.

## Contribution

A systematic review of how natural compounds modulate the PI3K/AKT pathway to treat MASLD/MASH, highlighting their therapeutic potential.

## Key findings

- Herbal medicines can alleviate MASLD/MASH by regulating the PI3K/AKT signaling pathway.
- Natural compounds like phenylpropanoids, flavonoids, and terpenoids show promise in targeting this pathway.
- Modulating the PI3K/AKT pathway through herbal treatments may help reverse liver disease progression.

## Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) was once known as non-alcoholic fatty liver disease (NAFLD). MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) have become significant challenges in global public health with their incidence rates showing a persistent upward trend. MASLD is the result of multiple factors acting simultaneously. Multiple biochemical cycles and molecular pathways are implicated in the pathogenesis of MASLD/MASH, such as the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) signaling pathway. Natural products are considered a treasure for new drug discovery and are of great value to medicine. Natural products mediate their therapeutic effects on MASLD/MASH, at least in part, by modulating the PI3K/AKT signaling pathway. However, at present, there are relatively few systematic reviews and summaries in this field both domestically and internationally. This review systematically examines the molecular mechanisms through which the PI3K/AKT signaling pathway contributes to the pathogenesis of MASLD/MASH. Additionally, it places particular emphasis on the potential of natural compounds targeting this pathway as a preventive strategy against MASLD/MASH. It is evident that the PI3K/AKT signaling pathway plays an important role in the progression of MASLD/MASH. Natural products belonging to various classes, such as phenylpropanoids, flavonoids, terpenoids, and alkaloids, can alleviate MASLD/MASH and the mechanisms involve regulation of the PI3K/AKT signaling pathway. Herbal medicines hold significant research potential in modulating the PI3K/AKT signaling pathway to improve MASLD/MASH. An in-depth understanding of these pharmacological mechanisms will help design precise intervention strategies to effectively interrupt or reverse disease progression.

Diagram showing the effects of herbal medicine on liver health. It includes chemical structures from plants and pathways like oxidative stress, lipid accumulation, autophagy, fibrosis, and inflammation. Arrows indicate progression from insulin resistance (IR) to a healthy liver, passing through stages marked by ROS, PI3K, Akt, GSK3, GLUT4, FOXO1, mTORC1, Nrf2, PPARα, and NF-κB. The process suggests the therapeutic impact of herbal extracts in managing MASLD/MASH and promoting liver health.

## Linked entities

- **Genes:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], gsk-3 (Glycogen synthase kinase-3) [NCBI Gene 173149], SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517], FOXO1 (forkhead box O1) [NCBI Gene 2308], Crtc (CREB-regulated transcription coactivator) [NCBI Gene 39970], GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Diseases:** MASLD (MONDO:0013209), MASH (MONDO:0007027)

## Full-text entities

- **Genes:** PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** MASH (MESH:D005234), NAFLD (MESH:D065626), MASLD (MESH:D008107)
- **Chemicals:** flavonoids (MESH:D005419), alkaloids (MESH:D000470), terpenoids (MESH:D013729), phenylpropanoids (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12832257/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12832257/full.md

## References

177 references — full list in the complete paper: https://tomesphere.com/paper/PMC12832257/full.md

---
Source: https://tomesphere.com/paper/PMC12832257